5-MeO-DET

5-MeO-DET
Identifiers
CAS Number	2454-70-8
PubChem (CID)	417608
ChemSpider	369669
ChEMBL	CHEMBL342986
Chemical and physical data
Formula	C15H22N2O
Molar mass	246.36 g/mol
3D model (Jmol)	Interactive image
	SMILES O(c1cc2c(cc1)ncc2CCN(CC)CC)C ;
	InChI InChI=1S/C15H22N2O/c1-4-17(5-2)9-8-12-11-16-15-7-6-13(18-3)10-14(12)15/h6-7,10-11,16H,4-5,8-9H2,1-3H3 ; Key:KGDVJQQWCDDEPP-UHFFFAOYSA-N ;
(what is this?) (verify)

5-MeO-DET or 5-methoxy-N,N-diethyltryptamine is a hallucinogenic tryptamine.

Pharmacology[edit]

5-MeO-DET inhibits serotonin reuptake with an IC₅₀ value of 2.4 µM and activates 5-HT_2A receptors with an EC₅₀ value of 8.11 nM.^[1]^[2]^[3]^[4]^[5]^[6]^[7]

Effects[edit]

Low dosages (0.5–1 mg) are reported to produce a relaxing body high and mild entheogenic effects. Shulgin reports in TiHKAL that higher dosages (1–3 mg) can produce very unpleasant reactions.

References[edit]

^ Meike Schulze-Alexandru; Karl-Artur Kovar; Angelo Vedani (December 1999). "Quasi-atomistic Receptor Surrogates for the 5-HT_2A Receptor: A 3D-QSAR Study on Hallucinogenic Substances". Quantitative Structure-Activity Relationships. 18 (6): 548–560. doi:10.1002/(SICI)1521-3838(199912)18:6<548::AID-QSAR548>3.0.CO;2-B.
^ Michael B. Gatch; Michael J. Forster; Aaron Janowsky; Amy J. Eshleman (April 2011). "Abuse Liability Profile of Three Substituted Tryptamines". Journal of Pharmacology and Experimental Therapeutics. 338 (1): 280–289. doi:10.1124/jpet.111.179705.
^ Richard A. Glennon; Peter K. Gessner (April 1979). "Serotonin receptor binding affinities of tryptamine analogs". Journal of Medicinal Chemistry. 22 (4): 428–432. doi:10.1021/jm00190a014. PMID 430481.
^ Adam L. Halberstadt; Mark A. Geyer (September 2011). "Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens". Neuropharmacology. 61 (3): 364–381. doi:10.1016/j.neuropharm.2011.01.017. PMC 3110631. PMID 21256140.
^ P.K. Gessner; D.D. Godse; A.H. Krull; J.M. McMullan (March 1968). "Structure-activity relationships among 5-methoxy-N:N-dimethyltryptamine, 4-hydroxy-N:N-dimethyltryptamine (psilocin) and other substituted tryptamines". Life Sciences. 7 (5): 267–277. doi:10.1016/0024-3205(68)90200-2.
^ Robert A. Lyon; Milt Titeler; Mark R. Seggel; Richard A. Glennon (January 1988). "Indolealkylamine analogs share 5-HT₂ binding characteristics with phenylalkylamine hallucinogens". European Journal of Pharmacology. 145 (3): 291–297. doi:10.1016/0014-2999(88)90432-3. PMID 3350047.
^ Bruce E. Blough; Antonio Landavazo; Ann M. Decker; John S. Partilla; Michael H. Baumann; Richard B. Rothman (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology. 231 (21): 4135–4144. doi:10.1007/s00213-014-3557-7. PMID 24800892.

External links[edit]

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Meike Schulze-Alexandru; Karl-Artur Kovar; Angelo Vedani (December 1999). "Quasi-atomistic Receptor Surrogates for the 5-HT_2A Receptor: A 3D-QSAR Study on Hallucinogenic Substances". Quantitative Structure-Activity Relationships. 18 (6): 548–560. doi:10.1002/(SICI)1521-3838(199912)18:6<548::AID-QSAR548>3.0.CO;2-B.

[2] Michael B. Gatch; Michael J. Forster; Aaron Janowsky; Amy J. Eshleman (April 2011). "Abuse Liability Profile of Three Substituted Tryptamines". Journal of Pharmacology and Experimental Therapeutics. 338 (1): 280–289. doi:10.1124/jpet.111.179705.

[3] Richard A. Glennon; Peter K. Gessner (April 1979). "Serotonin receptor binding affinities of tryptamine analogs". Journal of Medicinal Chemistry. 22 (4): 428–432. doi:10.1021/jm00190a014. PMID 430481.

[4] Adam L. Halberstadt; Mark A. Geyer (September 2011). "Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens". Neuropharmacology. 61 (3): 364–381. doi:10.1016/j.neuropharm.2011.01.017. PMC 3110631. PMID 21256140.

[5] P.K. Gessner; D.D. Godse; A.H. Krull; J.M. McMullan (March 1968). "Structure-activity relationships among 5-methoxy-N:N-dimethyltryptamine, 4-hydroxy-N:N-dimethyltryptamine (psilocin) and other substituted tryptamines". Life Sciences. 7 (5): 267–277. doi:10.1016/0024-3205(68)90200-2.

[6] Robert A. Lyon; Milt Titeler; Mark R. Seggel; Richard A. Glennon (January 1988). "Indolealkylamine analogs share 5-HT₂ binding characteristics with phenylalkylamine hallucinogens". European Journal of Pharmacology. 145 (3): 291–297. doi:10.1016/0014-2999(88)90432-3. PMID 3350047.

[7] Bruce E. Blough; Antonio Landavazo; Ann M. Decker; John S. Partilla; Michael H. Baumann; Richard B. Rothman (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology. 231 (21): 4135–4144. doi:10.1007/s00213-014-3557-7. PMID 24800892.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

5-MeO-DET

Contents

Pharmacology[edit]

Effects[edit]

See also[edit]

References[edit]

External links[edit]

Navigation menu

Personal tools

Namespaces

Variants

Views

More

Search

Navigation

Interaction

Tools

Print/export

Languages

Identifiers

CAS Number	2454-70-8^N
PubChem (CID)	417608
ChemSpider	369669^Y
ChEMBL	CHEMBL342986^Y
Chemical and physical data
Formula	C₁₅H₂₂N₂O
Molar mass	246.36 g/mol
3D model (Jmol)	Interactive image
SMILES O(c1cc2c(cc1)ncc2CCN(CC)CC)C
InChI InChI=1S/C15H22N2O/c1-4-17(5-2)9-8-12-11-16-15-7-6-13(18-3)10-14(12)15/h6-7,10-11,16H,4-5,8-9H2,1-3H3^Y Key:KGDVJQQWCDDEPP-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)